Butyrate supplements have been shown to help improve symptoms of IBS and traveler’s diarrhea, and to help improve bacterial balance in the gut microbiome.
On the other hand, butyrate supplements have been shown not to help with ulcerative colitis, and might trigger symptoms for people with certain gut problems.
Butyrate is produced by a healthy microbiota. It provides energy for the gut lining and may help keep the colon healthy.
Butyrate supplements are becoming popular. So is promoting butyrate production with prebiotic food or supplements.
For people who have a sensitive gut, a lower fiber regimen is better than additional fiber and butyrate.
Research shows the low FODMAP diet can relieve gut symptoms and offer benefits despite a probable temporary decrease in butyrate levels.
Focusing on reducing symptoms allows the gut to heal. You can increase the fiber in your diet (to optimize butyrate levels) in time, when your gut is healthier.
Butyrate is a new buzzword in gut health. Butyrate supplements and prebiotics that stimulate your gut to produce butyrate are often promoted as a way to help gut health problems, as butyrate theoretically has a number of digestive system benefits.
But does research back the benefits of butyrate supplements? In this article, we’ll look at butyrate, its functions, and whether upping your intake by taking butyrate supplements can help conditions such as IBS, dysbiosis, weight loss, and inflammatory bowel disease.
What Is Butyrate?
Butyrate (butyric acid) is a short chain fatty acid (SCFA). That means it’s a type of “good fat,” though it’s not widely found in food. Butter is the best source, but most of the butyrate in our bodies is produced by bacteria in the bowels [1 Trusted SourcePubMedGo to source].
Good gut bacteria that live in the colon “eat”, or ferment, fiber and carbs (such as resistant starch) our gastrointestinal tract can’t digest. This fermentation process produces SCFAs as a byproduct. Of these, butyrate is the most well known. Other common SCFAs include propionate and acetate.
Prebiotics, such as resistant starch and fructose-oligosaccharides found in food and supplements can feed butyrate-producing gut bacteria, in turn increasing the amount of butyrate that is available in the gut.
Supplements of butyrate are fairly new, so we’re still learning what effects they may have. Current studies suggest several potential benefits but some reasons to be cautious too.
When it comes to taking butyrate supplements, the rationale is essentially that more butyrate = better gut health. However, this is not necessarily true in all cases. For example, while patients with certain types of digestive conditions have been shown to have lower levels of butyrate in their guts, patients with other conditions have been shown to have higher levels. In other words, more butyrate doesn’t automatically equal better gut health.
A few clinical trials have shown that butyrate can help to improve symptoms of IBS, diverticulitis, and traveler’s diarrhea. However, there is much more evidence to support interventions like the low FODMAP diet — which may actually decrease butyrate levels — for the treatment of IBS, SIBO, and other digestive conditions.
The bottom line is that while butyrate supplements may offer benefits in some cases, they’re not the first step if you’re experiencing digestive symptoms. And if you do try a butyrate supplement, make sure to monitor your symptoms. That way, you can see if they’re improving, staying the same, or worsening. If the latter occurs, of course, you’ll want to discontinue supplementation.
IBS (irritable bowel syndrome): A 2013 RCT involving 60 patients with IBS found that 12 weeks of sodium butyrate supplementation (on top of standard medicinal therapy) was associated with significantly decreased abdominal pain, reduced pain during bowel movements, and less constipation compared to placebo supplementation [12 Trusted SourcePubMedGo to source].
Diverticulitis: A 2014 RCT found that 12 months of supplementation with sodium butyrate (300 mg per day) was associated with a significantly decreased episodes of diverticulitis (acute inflammation of pouches that can form in the intestine) compared to a control group. Subjective quality of life was also higher in the sodium butyrate group compared to the control group [13 Trusted SourcePubMedGo to source].
Traveler’s diarrhea: Sodium butyrate (250 mg per day) taken for three days in combination with other SCFAs before and during traveling was associated with a reduced risk of abdominal symptoms like pain, bloating, nausea, and fevers [14 Trusted SourcePubMedGo to source].
The Bad News
Obesity and impaired glucose tolerance: However, levels of butyrate seem higher in obese people [15 Trusted SourcePubMedGo to source, 16 Trusted SourcePubMedGo to source]. So, consuming extra butyrate in the form of supplements probably isn’t a good idea if you already have weight issues, diabetes, or metabolic syndrome.
A 2019 observational study involving 441 adults found that higher fecal butyrate levels were significantly associated with obesity, high blood pressure, poor metabolic health (including raised cholesterol, triglycerides, and blood sugar), more gut permeability (a leaky gut), and gut dysbiosis [17 Trusted SourcePubMedGo to source].
In animal research, butyrate supplements given to pregnant and lactating rats induced insulin resistance and fat deposition in the offspring [18 Trusted SourcePubMedGo to source].
Ulcerative colitis: A 2021 systematic review of eight separate trials involving 227 patients with ulcerative colitis found that, on balance, butyrateenemas did not help the condition [20 Trusted SourcePubMedGo to source].
Only one trial showed improvement in disease activity compared to controls.
Butyrate treatment did not significantly improve inflammation or the health of tissues examined via endoscopy (a camera down the throat).
Autism in children: Increased levels of SCFAs in the bloodstream due to increased gut permeability or abnormal microbiota may actually be detrimental to children with autism.
While the underlying issue here is much more likely to be the leaky gut and dysbiosis, it still seems wise for pregnant women and infants not to be exposed to large amounts of supplemental butyrate or other SCFAs [1 Trusted SourcePubMedGo to source].
But while a high-fiber diet is a key way to feed the gut microbes and optimize butyrate production in healthy people, it can have the opposite effect in people who already have compromised gut health.
Many people with bloating and gut sensitivity find their symptoms worsen with the intake of some types of carbohydrates and dietary fibers. In these people, a low FODMAP diet (which minimizes the intake of carbohydrates and fibers that can trigger gut sensitivities) is often a much safer and more effective option.
Strong research supports that the low FODMAP diet can:
Improve IBS symptom severity and offer significantly better quality of life to IBS patients (compared with control diets) [22 Trusted SourcePubMedGo to source]
The low FODMAP diet is an elimination diet that cuts out fermentable carbohydrates found in foods such as wheat, milk, onion, mangos, asparagus, and garlic. There are three main phases of the diet:
Elimination: During this initial stage of the diet, you avoid high FODMAP foods for up to three weeks in order to obtain quick relief of symptoms such as bloating, abdominal pain, flatulence, and diarrhea.
Food reintroduction: In the reintroduction phase, you test one high FODMAP food at a time in order to identify which FODMAP foods most aggravate your symptoms.
Personalizing and maintaining: In this phase, you use what you’ve learned during the elimination and reintroduction phases to broaden your diet (as long as symptoms stay reduced).
The low FODMAP diet has been shown to temporarily reduce butyrate production as well as gut microbiota diversity. Gut bacteria diversity is usually a sign of a robust and healthy gut flora [25 Trusted SourcePubMedGo to source, 26 Trusted SourcePubMedGo to source]. However, it’s still a much better option than increasing prebiotic fiber intake and/or taking butyrate supplements for people who have recent gut issues.
This helps us to see that higher butyrate levels are not necessary for better gut health or improved symptoms: On a low FODMAP diet, symptoms often significantly improve, even if butyrate levels are decreased.
In one randomized controlled trial, short-chain fatty acids and butyrate were significantly lower after people began a low FODMAP diet, but signs of inflammation were also significantly lower — a sign that the gut is beginning to heal [25 Trusted SourcePubMedGo to source].
Later on, when your gut has begun healing and you have built up some tolerance, you can very likely reintroduce and consume enough healthy high fiber foods to optimize butyrate production.
Probiotics Supplements Are Tried and Tested
Before experimenting with butyrate supplements, it makes sense for people with inflammation, gut dysbiosis, and other gut issues to take a well-formulated broad spectrum probiotic supplement. Extensive research shows that they can:
A recent literature review to determine the effect of probiotics on butyrate and other SCFA production in the microbiome found only one study involving humans where butyrate and other SCFAs increased [34 Trusted SourcePubMedGo to source].
The same review found cell and animal studies where butyrate production increased from taking probiotics. However all the other other clinical trials, which involved both healthy and unwell patients did not mention increases in butyrate from supplementing with Lactobacillus or Bifidobacteria probiotics.
Though probiotics are really useful for gut health, it appears that increasing butyrate isn’t a primary route of action.
The Bottom Line on Butyrate Supplements
Butyrate undoubtedly has important roles to play in gut health. Ordinarily (in people with robust gut health), a varied diet including different plant fibers and prebiotics will help your gut bacteria create optimal levels of butyrate without the need for butyrate supplements.
However, for a sensitive gut, strong, research-based evidence supports cutting down on fermentable carbs and fibers through a low FODMAP diet.
Research suggests butyrate supplements can have some positive effects on gut health but may have negative effects in some situations, particularly in obesity where levels are often already raised anyway.
The Ruscio Institute has developed a range of high quality probiotics to help our patients and audience. If you’re interested in learning more about these products, please click here. Note that there are many other options available, and we encourage you to research which products may be right for you.
Bourassa MW, Alim I, Bultman SJ, Ratan RR. Butyrate, neuroepigenetics and the gut microbiome: Can a high fiber diet improve brain health? Neurosci Lett. 2016 Jun 20;625:56–63. DOI: 10.1016/j.neulet.2016.02.009. PMID: 26868600. PMCID: PMC4903954. Trusted SourcePubMedGo to source
Verhoog S, Taneri PE, Roa Díaz ZM, Marques-Vidal P, Troup JP, Bally L, et al. Dietary Factors and Modulation of Bacteria Strains of Akkermansia muciniphila and Faecalibacterium prausnitzii: A Systematic Review. Nutrients. 2019 Jul 11;11(7). DOI: 10.3390/nu11071565. PMID: 31336737. PMCID: PMC6683038. Trusted SourcePubMedGo to source
Shen D, Bai H, Li Z, Yu Y, Zhang H, Chen L. Positive effects of resistant starch supplementation on bowel function in healthy adults: a systematic review and meta-analysis of randomized controlled trials. Int J Food Sci Nutr. 2017 Mar;68(2):149–57. DOI: 10.1080/09637486.2016.1226275. PMID: 27593182. Trusted SourcePubMedGo to source
Serrano-Villar S, Vázquez-Castellanos JF, Vallejo A, Latorre A, Sainz T, Ferrando-Martínez S, et al. The effects of prebiotics on microbial dysbiosis, butyrate production and immunity in HIV-infected subjects. Mucosal Immunol. 2017 Sep;10(5):1279–93. DOI: 10.1038/mi.2016.122. PMID: 28000678. Trusted SourcePubMedGo to source
Valcheva R, Koleva P, Martínez I, Walter J, Gänzle MG, Dieleman LA. Inulin-type fructans improve active ulcerative colitis associated with microbiota changes and increased short-chain fatty acids levels. Gut Microbes. 2019;10(3):334–57. DOI: 10.1080/19490976.2018.1526583. PMID: 30395776. PMCID: PMC6546336. Trusted SourcePubMedGo to source
Liu H, Wang J, He T, Becker S, Zhang G, Li D, et al. Butyrate: A Double-Edged Sword for Health? Adv Nutr. 2018 Jan 1;9(1):21–9. DOI: 10.1093/advances/nmx009. PMID: 29438462. PMCID: PMC6333934. Trusted SourcePubMedGo to source
Couto MR, Gonçalves P, Magro F, Martel F. Microbiota-derived butyrate regulates intestinal inflammation: Focus on inflammatory bowel disease. Pharmacol Res. 2020 Sep;159:104947. DOI: 10.1016/j.phrs.2020.104947. PMID: 32492488. Trusted SourcePubMedGo to source
Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol. 2014;121:91–119. DOI: 10.1016/B978-0-12-800100-4.00003-9. PMID: 24388214. Trusted SourcePubMedGo to source
Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008 Jan 15;27(2):104–19. DOI: 10.1111/j.1365-2036.2007.03562.x. PMID: 17973645. Trusted SourcePubMedGo to source
Roshanravan N, Mahdavi R, Alizadeh E, Ghavami A, Rahbar Saadat Y, Mesri Alamdari N, et al. The effects of sodium butyrate and inulin supplementation on angiotensin signaling pathway via promotion of Akkermansia muciniphila abundance in type 2 diabetes; A randomized, double-blind, placebo-controlled trial. J Cardiovasc Thorac Res. 2017 Nov 25;9(4):183–90. DOI: 10.15171/jcvtr.2017.32. PMID: 29391930. PMCID: PMC5787329. Trusted SourcePubMedGo to source
Facchin S, Vitulo N, Calgaro M, Buda A, Romualdi C, Pohl D, et al. Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. Neurogastroenterol Motil. 2020 Oct;32(10):e13914. DOI: 10.1111/nmo.13914. PMID: 32476236. PMCID: PMC7583468. Trusted SourcePubMedGo to source
Banasiewicz T, Krokowicz Ł, Stojcev Z, Kaczmarek BF, Kaczmarek E, Maik J, et al. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis. 2013 Feb;15(2):204–9. DOI: 10.1111/j.1463-1318.2012.03152.x. PMID: 22738315. Trusted SourcePubMedGo to source
Krokowicz L, Stojcev Z, Kaczmarek BF, Kociemba W, Kaczmarek E, Walkowiak J, et al. Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis–a prospective randomized study. Int J Colorectal Dis. 2014 Mar;29(3):387–93. DOI: 10.1007/s00384-013-1807-5. PMID: 24343275. PMCID: PMC3936115. Trusted SourcePubMedGo to source
Krokowicz L, Kaczmarek BF, Krokowicz P, Stojcev Z, Mackiewicz J, Walkowiak J, et al. Sodium butyrate and short chain fatty acids in prevention of travellers’ diarrhoea: a randomized prospective study. Travel Med Infect Dis. 2014 Apr;12(2):183–8. DOI: 10.1016/j.tmaid.2013.08.008. PMID: 24063909. Trusted SourcePubMedGo to source
Kim KN, Yao Y, Ju SY. Short Chain Fatty Acids and Fecal Microbiota Abundance in Humans with Obesity: A Systematic Review and Meta-Analysis. Nutrients. 2019 Oct 18;11(10). DOI: 10.3390/nu11102512. PMID: 31635264. PMCID: PMC6835694. Trusted SourcePubMedGo to source
Schwiertz A, Taras D, Schäfer K, Beijer S, Bos NA, Donus C, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 2010 Jan;18(1):190–5. DOI: 10.1038/oby.2009.167. PMID: 19498350. Trusted SourcePubMedGo to source
de la Cuesta-Zuluaga J, Mueller NT, Álvarez-Quintero R, Velásquez-Mejía EP, Sierra JA, Corrales-Agudelo V, et al. Higher Fecal Short-Chain Fatty Acid Levels Are Associated with Gut Microbiome Dysbiosis, Obesity, Hypertension and Cardiometabolic Disease Risk Factors. Nutrients. 2018 Dec 27;11(1). DOI: 10.3390/nu11010051. PMID: 30591685. PMCID: PMC6356834. Trusted SourcePubMedGo to source
Huang Y, Gao S, Chen J, Albrecht E, Zhao R, Yang X. Maternal butyrate supplementation induces insulin resistance associated with enhanced intramuscular fat deposition in the offspring. Oncotarget. 2017 Feb 21;8(8):13073–84. DOI: 10.18632/oncotarget.14375. PMID: 28055958. PMCID: PMC5355078. Trusted SourcePubMedGo to source
Birt DF, Boylston T, Hendrich S, Jane J-L, Hollis J, Li L, et al. Resistant starch: promise for improving human health. Adv Nutr. 2013 Nov 6;4(6):587–601. DOI: 10.3945/an.113.004325. PMID: 24228189. PMCID: PMC3823506. Trusted SourcePubMedGo to source
Jamka M, Kokot M, Kaczmarek N, Bermagambetova S, Nowak JK, Walkowiak J. The Effect of Sodium Butyrate Enemas Compared with Placebo on Disease Activity, Endoscopic Scores, and Histological and Inflammatory Parameters in Inflammatory Bowel Diseases: A Systematic Review of Randomised Controlled Trials. Complement Med Res. 2021;28(4):344–56. DOI: 10.1159/000512952. PMID: 33352566. Trusted SourcePubMedGo to source
Zhang M, Wang Y, Zhao X, Liu C, Wang B, Zhou J. Mechanistic basis and preliminary practice of butyric acid and butyrate sodium to mitigate gut inflammatory diseases: a comprehensive review. Nutr Res. 2021 Sep 9;95:1–18. DOI: 10.1016/j.nutres.2021.08.007. PMID: 34757305. Trusted SourcePubMedGo to source
van Lanen A-S, de Bree A, Greyling A. Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis. Eur J Nutr. 2021 Sep;60(6):3505–22. DOI: 10.1007/s00394-020-02473-0. PMID: 33585949. PMCID: PMC8354978. Trusted SourcePubMedGo to source
Schumann D, Klose P, Lauche R, Dobos G, Langhorst J, Cramer H. Low fermentable, oligo-, di-, mono-saccharides and polyol diet in the treatment of irritable bowel syndrome: A systematic review and meta-analysis. Nutrition. 2018 Jan;45:24–31. DOI: 10.1016/j.nut.2017.07.004. PMID: 29129233. Trusted SourcePubMedGo to source
Cox SR, Lindsay JO, Fromentin S, Stagg AJ, McCarthy NE, Galleron N, et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology. 2020 Jan;158(1):176-188.e7. DOI: 10.1053/j.gastro.2019.09.024. PMID: 31586453. Trusted SourcePubMedGo to source
Hustoft TN, Hausken T, Ystad SO, Valeur J, Brokstad K, Hatlebakk JG, et al. Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2017 Apr;29(4). DOI: 10.1111/nmo.12969. PMID: 27747984. Trusted SourcePubMedGo to source
Vandeputte D, Joossens M. Effects of Low and High FODMAP Diets on Human Gastrointestinal Microbiota Composition in Adults with Intestinal Diseases: A Systematic Review. Microorganisms. 2020 Oct 23;8(11). DOI: 10.3390/microorganisms8111638. PMID: 33114017. PMCID: PMC7690730. Trusted SourcePubMedGo to source
Wang F, Feng J, Chen P, Liu X, Ma M, Zhou R, et al. Probiotics in Helicobacter pylori eradication therapy: Systematic review and network meta-analysis. Clin Res Hepatol Gastroenterol. 2017 Sep;41(4):466–75. DOI: 10.1016/j.clinre.2017.04.004. PMID: 28552432. Trusted SourcePubMedGo to source
García-Collinot G, Madrigal-Santillán EO, Martínez-Bencomo MA, Carranza-Muleiro RA, Jara LJ, Vera-Lastra O, et al. Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis. Dig Dis Sci. 2020 Apr;65(4):1134–43. DOI: 10.1007/s10620-019-05830-0. PMID: 31549334. Trusted SourcePubMedGo to source
Greco A, Caviglia GP, Brignolo P, Ribaldone DG, Reggiani S, Sguazzini C, et al. Glucose breath test and Crohn’s disease: Diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response. Scand J Gastroenterol. 2015 May 19;50(11):1376–81. DOI: 10.3109/00365521.2015.1050691. PMID: 25990116. Trusted SourcePubMedGo to source
Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol. 2009 Feb 16;9:15. DOI: 10.1186/1471-230X-9-15. PMID: 19220890. PMCID: PMC2656520. Trusted SourcePubMedGo to source
Sindhu KNC, Sowmyanarayanan TV, Paul A, Babji S, Ajjampur SSR, Priyadarshini S, et al. Immune response and intestinal permeability in children with acute gastroenteritis treated with Lactobacillus rhamnosus GG: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2014 Apr;58(8):1107–15. DOI: 10.1093/cid/ciu065. PMID: 24501384. PMCID: PMC3967829. Trusted SourcePubMedGo to source
Lamprecht M, Bogner S, Schippinger G, Steinbauer K, Fankhauser F, Hallstroem S, et al. Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men; a randomized, double-blinded, placebo-controlled trial. J Int Soc Sports Nutr. 2012 Sep 20;9(1):45. DOI: 10.1186/1550-2783-9-45. PMID: 22992437. PMCID: PMC3465223. Trusted SourcePubMedGo to source
Markowiak-Kopeć P, Śliżewska K. The Effect of Probiotics on the Production of Short-Chain Fatty Acids by Human Intestinal Microbiome. Nutrients. 2020 Apr 16;12(4). DOI: 10.3390/nu12041107. PMID: 32316181. PMCID: PMC7230973. Trusted SourcePubMedGo to source
➕ Links & Resources
Butyrate Producing Probiotics
Need help or would like to learn more? View Dr. Ruscio’s additional resources
I care about answering your questions and sharing my knowledge with you. Leave a comment or connect with me on social media asking any health question you may have and I just might incorporate it into our next listener questions podcast episode just for you!
Transform your health
Every product is science-based, validated by real-world use, and personally vetted by Dr. Ruscio, DNM, DC.